Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Terminated Phase 4 Interventional

Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias

NCT01623583
View directory record Official record
Conditions
Needle Phobia, Phobic Disorders
Interventions
Enhanced Needle Phobia Intervention, Standard Needle Phobia Intervention
Other
Lead sponsor
Davita Clinical Research
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Rancho Cordova, California • Sacramento, California • Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 26, 2026, 7:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

NCT04337970
View directory record Official record
Conditions
Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Talazoparib, Axitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 26, 2026, 7:14 PM EDT
Recruiting Phase 3 Interventional

R.E.C.K vs Exparel in Robotic Nephrectomy

NCT07092566
View directory record Official record
Conditions
Renal Carcinoma, Nephrectomy / Methods, Pain Management
Interventions
Ropivacaine HCL, Exparel, Epinephrine, Clonidine HCL, Ketorolac
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 26, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor

NCT02944617
View directory record Official record
Conditions
Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Micronutrient-Fortified Probiotic Yogurt, VEGF-TKI
Other · Dietary Supplement · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 26, 2026, 7:14 PM EDT
Withdrawn Phase 4 Interventional

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

NCT03093740
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
Zepatier, Zepatier plus Sofosbuvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 26, 2026, 7:14 PM EDT
Completed Phase 3 Interventional

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

NCT00255424
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol or oral iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
19
States / cities
Encino, California • Riverside, California • Tarzana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 26, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 26, 2026, 7:14 PM EDT
Completed No phase listed Observational

Fluid Balance and Clinical Outcomes

NCT01168583
View directory record Official record
Conditions
Fluid Balance, Input and Output, Inflammatory Mediators, Acute Kidney Injury, Mortality
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 26, 2026, 7:14 PM EDT
Active, not recruiting Not applicable Interventional

Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

NCT05613010
View directory record Official record
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Liver, Adherence, Medication, Adherence, Patient, Adherence, Treatment
Interventions
mHealth Messaging Intervention Group
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 26, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

NCT03988920
View directory record Official record
Conditions
Hyperphosphatemia, End Stage Renal Disease
Interventions
Tenapanor, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
Not listed
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 26, 2026, 7:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of The CKM JumpStart Tool

NCT05753020
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
CKM Jumpstart Tool
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
75 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 26, 2026, 7:14 PM EDT
Withdrawn Not applicable Interventional

Altering Bicarbonate Delivery During Hemodialysis to Affect Filtration of Indoxyl Sulfate

NCT02639624
View directory record Official record
Conditions
Renal Dialysis, Hemodialysis
Interventions
Low bicarbonate dialysate First, Normal bicarbonate dialysate First, Normal bicarbonate dialysate, Low bicarbonate dialysate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 26, 2026, 7:14 PM EDT
Recruiting No phase listed Observational

Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT05692388
View directory record Official record
Conditions
Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, Chronic Kidney Diseases
Interventions
Patient and Community Stakeholder Interviews, Cross-sectional Study Participants, Focus Groups and Intervention Mapping
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 26, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

NCT04225988
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Extended-release tacrolimus, Immediate-release tacrolimus
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 26, 2026, 7:14 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Vasodilators and Anti-Oxidant Therapy in Early ATN

NCT00286403
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Fenoldopam Mesylate and/or MESNA
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 26, 2026, 7:14 PM EDT
Completed No phase listed Observational Results available

Real World Glycemic Effectiveness of Linagliptin

NCT03338803
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 26, 2026, 7:14 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Spleen Transplant in Solid Organ Transplantation

NCT04827186
View directory record Official record
Conditions
Kidney Transplant Rejection, Positive FCXM (T or B Cell Positive), Positive CDC Cross-Match (B Cell Positive), Kidney/Pancreas Transplant Rejection
Interventions
Spleen Transplantation/Removal
Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 26, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Venglustat in Patients With Renal Impairment

NCT03687554
View directory record Official record
Conditions
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 26, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

NCT02866682
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 26, 2026, 7:14 PM EDT
Active, not recruiting No phase listed Observational

Cardiopulmonary Bypass Induced Red Blood Cell Lysis

NCT05189262
View directory record Official record
Conditions
Cardiopulmonary Bypass, Cardiac Surgery, Kidney Injury, Acute
Interventions
Blood and urine collection
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 26, 2026, 7:14 PM EDT
Completed No phase listed Observational

Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients

NCT05964088
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 26, 2026, 7:14 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 26, 2026, 7:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

NCT05365451
View directory record Official record
Conditions
Interaction, Endogenous Biomarkers
Interventions
MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product, Probenecid 500 MG
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 26, 2026, 7:14 PM EDT
Recruiting Phase 2 Interventional

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

NCT06447103
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Zirconium Zr 89 Girentuximab
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 7:14 PM EDT